CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 162 enrolled
Drug / intervention
Fumaric Acid Esters +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02634801
NCT02634801Phase 3Completed
CompareCT.gov

A 24-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients With Moderate-to-Severe Plaque Psoriasis Who Are Naive to Systemic Treatment With an Extension Period

Eli Lilly and Company·interventional·Posted Dec 18, 2015·Updated Oct 9, 2019

In Brief

A Phase 3 clinical trial evaluating Fumaric Acid Esters, Methotrexate, and 1 other intervention for Plaque Psoriasis. Completed, enrolled 162 participants across 21 sites.

Detailed Summary

The main purpose of this study is to evaluate the efficacy of ixekizumab compared to fumaric acid esters (FAE) and methotrexate (MTX) in participants with moderate-to-severe plaque psoriasis who are naive to systemic treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 18, 2015
Enrollment StartJan 20, 2016
Primary CompletionNov 29, 2016
Study CompletionNov 14, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.5 years ago

Interventions

Fumaric Acid Estersdrug

Administered orally

Methotrexatedrug

Administered orally

Ixekizumabdrug

Administered SC